MCID: ADL096
MIFTS: 56

Adult Hepatocellular Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Adult Hepatocellular Carcinoma

MalaCards integrated aliases for Adult Hepatocellular Carcinoma:

Name: Adult Hepatocellular Carcinoma 12 59
Adult Primary Hepatocellular Carcinoma 12 72
Adult Hepatoma 12
Adult Hcc 59

Characteristics:

Orphanet epidemiological data:

59
adult hepatocellular carcinoma
Inheritance: Not applicable;

Classifications:

Orphanet: 59  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:0070328
NCIt 50 C7956
ICD10 via Orphanet 34 C22.0
Orphanet 59 ORPHA210159
UMLS 72 C0279607

Summaries for Adult Hepatocellular Carcinoma

Disease Ontology : 12 A hepatocellular carcinoma that is characterized by hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure and often develops in the setting of chronic necro-inflammation.

MalaCards based summary : Adult Hepatocellular Carcinoma, also known as adult primary hepatocellular carcinoma, is related to hepatocellular carcinoma and pediatric hepatocellular carcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Adult Hepatocellular Carcinoma is AXIN1 (Axin 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Tamoxifen and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Adult Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Adult Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 28.2 TP53 PIK3CA PDGFRL CTNNB1 CASP8 AXIN1
2 pediatric hepatocellular carcinoma 11.4
3 prostate transitional cell carcinoma 10.4 PIK3CA CTNNB1
4 hemimegalencephaly 10.3 PIK3CA CTNNB1
5 rare adenocarcinoma of the breast 10.2 TP53 PIK3CA
6 malignant spiradenoma 10.2 TP53 PIK3CA
7 uterine corpus serous adenocarcinoma 10.2 TP53 PIK3CA
8 epstein-barr virus-associated gastric carcinoma 10.2 PIK3CA CTNNB1
9 breast squamous cell carcinoma 10.2 TP53 PIK3CA
10 uterine body mixed cancer 10.2 TP53 PIK3CA
11 anal squamous cell carcinoma 10.2 TP53 PIK3CA
12 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.1 TP53 PIK3CA
13 female reproductive endometrioid cancer 10.1 TP53 CTNNB1
14 uterine corpus cancer 10.1 TP53 PIK3CA
15 tongue disease 10.0 TP53 CTNNB1
16 ovary adenocarcinoma 10.0 TP53 PIK3CA
17 maxillary cancer 10.0 TP53 EGF
18 acinar cell carcinoma 10.0 TP53 CTNNB1
19 macrodactyly 10.0 TSC1 PIK3CA
20 gastrointestinal system benign neoplasm 10.0 TP53 CTNNB1
21 central nervous system benign neoplasm 9.9 TSC2 TP53
22 intestinal benign neoplasm 9.9 TP53 CTNNB1
23 esophageal basaloid squamous cell carcinoma 9.9 TP53 CTNNB1 AXIN1
24 embryonal sarcoma 9.9 TP53 CTNNB1 AXIN1
25 oral cavity cancer 9.9 TP53 PIK3CA CASP8
26 skin squamous cell carcinoma 9.9 TP53 PIK3CA
27 familial adenomatous polyposis 9.9 TP53 CTNNB1 AXIN1
28 kidney angiomyolipoma 9.9 TSC2 TSC1
29 angiomyolipoma 9.9 TSC2 TSC1
30 uterine anomalies 9.9 TP53 PIK3CA CTNNB1
31 carcinosarcoma 9.9 TP53 PIK3CA CTNNB1
32 respiratory system cancer 9.9 TP53 PIK3CA CTNNB1
33 subependymal glioma 9.9 TSC2 TSC1
34 uterine carcinosarcoma 9.8 TP53 PIK3CA CTNNB1
35 intestinal disease 9.8 TP53 PIK3CA CTNNB1
36 benign ependymoma 9.8 TSC2 TSC1
37 gastrointestinal system cancer 9.8 TP53 PIK3CA CTNNB1
38 suppression of tumorigenicity 12 9.8 TP53 PIK3CA CTNNB1
39 lissencephaly with cerebellar hypoplasia 9.8 TSC2 TSC1
40 infratentorial cancer 9.8 TP53 CTNNB1
41 adrenocortical carcinoma, hereditary 9.8 TP53 PIK3CA CTNNB1
42 melanoma, cutaneous malignant 1 9.8 TP53 PIK3CA CTNNB1
43 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8 TSC2 TSC1
44 bladder urothelial carcinoma 9.8 TP53 PIK3CA CTNNB1
45 penile cancer 9.8 TP53 PIK3CA
46 alcohol dependence 9.8
47 non-alcoholic steatohepatitis 9.8
48 sarcoma 9.8
49 hemangioma 9.8
50 cavernous hemangioma 9.8

Graphical network of the top 20 diseases related to Adult Hepatocellular Carcinoma:



Diseases related to Adult Hepatocellular Carcinoma

Symptoms & Phenotypes for Adult Hepatocellular Carcinoma

UMLS symptoms related to Adult Hepatocellular Carcinoma:


fever, abdominal pain, icterus, malaise

MGI Mouse Phenotypes related to Adult Hepatocellular Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
2 growth/size/body region MP:0005378 10.06 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
3 cellular MP:0005384 10.05 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
4 embryo MP:0005380 10.04 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
5 endocrine/exocrine gland MP:0005379 10.02 CASP8 CTNNB1 EGF PIK3CA TP53 TSC1
6 integument MP:0010771 9.98 CASP8 CTNNB1 EGF PIK3CA TP53 TSC1
7 liver/biliary system MP:0005370 9.8 CASP8 CTNNB1 TP53 TSC1 TSC2
8 neoplasm MP:0002006 9.8 CASP8 CTNNB1 PIK3CA TP53 TSC1 TSC2
9 nervous system MP:0003631 9.8 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
10 muscle MP:0005369 9.77 CASP8 CTNNB1 PIK3CA TP53 TSC1
11 renal/urinary system MP:0005367 9.63 AXIN1 CASP8 CTNNB1 TP53 TSC1 TSC2
12 reproductive system MP:0005389 9.5 AXIN1 CTNNB1 EGF PIK3CA TP53 TSC1
13 respiratory system MP:0005388 9.02 AXIN1 CASP8 CTNNB1 TP53 TSC1

Drugs & Therapeutics for Adult Hepatocellular Carcinoma

Drugs for Adult Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 3 10540-29-1 2733526
2
Sodium citrate Approved, Investigational Phase 3 68-04-2
3
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
4
Iodine Approved, Investigational Phase 3 7553-56-2 807
5 Ethiodized oil Approved, Investigational Phase 3 8008-53-5
6
leucovorin Approved Phase 3 58-05-9 143 6006
7
Pravastatin Approved Phase 3 81093-37-0 54687
8
Gemcitabine Approved Phase 3 95058-81-4 60750
9
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
10
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
11
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
12
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
13
Fluorouracil Approved Phase 3 51-21-8 3385
14
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
15
Etoposide Approved Phase 3 33419-42-0 36462
16
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
17
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
18
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20 Nolatrexed Investigational Phase 3 147149-76-6
21 Citrate Phase 3
22 Selective Estrogen Receptor Modulators Phase 3
23 Estrogen Receptor Modulators Phase 3
24 Estrogen Receptor Antagonists Phase 3
25 Estrogen Antagonists Phase 3
26 Bone Density Conservation Agents Phase 3
27 Contraceptives, Oral Phase 3
28 Contraceptive Agents Phase 3
29 Appetite Stimulants Phase 3
30
Megestrol Phase 3 3562-63-8 3080587 19090
31 Micronutrients Phase 3
32 Anti-Infective Agents, Local Phase 3
33 Nutrients Phase 3
34 cadexomer iodine Phase 3
35 Trace Elements Phase 3
36 Folic Acid Antagonists Phase 3
37 Folate Phase 3
38 Vitamin B Complex Phase 3
39 Vitamin B9 Phase 3
40 Lipid Regulating Agents Phase 3
41 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
42 Hypolipidemic Agents Phase 3
43 Anticholesteremic Agents Phase 3
44 Immunologic Factors Phase 3
45 Antimetabolites, Antineoplastic Phase 3
46 Antimetabolites Phase 3
47 Tubulin Modulators Phase 3
48 Immunosuppressive Agents Phase 3
49 Anti-Infective Agents Phase 3
50 Antimitotic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma Unknown status NCT00079027 Phase 3 doxorubicin hydrochloride
2 TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer Unknown status NCT01324076 Phase 3 doxorubicin-eluting beads;sorafenib tosylate
3 Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma Completed NCT00003424 Phase 3 tamoxifen citrate
4 Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma Completed NCT00041275 Phase 3 megestrol acetate
5 Adjuvant Treatment by Intra-arterial Injection of Lipiodol-labeled Iodine-131 in Preventing Recurrence of Hepatocellular Carcinoma After Curative Treatment Completed NCT00870558 Phase 3 ethiodized oil
6 A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin Completed NCT00012324 Phase 3 doxorubicin hydrochloride;nolatrexed dihydrochloride
7 A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE) Completed NCT01164202 Phase 2, Phase 3 sunitinib malate;Placebo
8 Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma Completed NCT01075555 Phase 3 pravastatin sodium;sorafenib tosylate
9 A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study) Completed NCT01829035 Phase 3
10 A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC) Completed NCT00109954 Phase 3 cisplatin
11 Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma Recruiting NCT01730937 Phase 3 sorafenib tosylate
12 Paediatric Hepatic International Tumour Trial Recruiting NCT03017326 Phase 3 Cisplatin;Doxorubicin;Carboplatin;5Fluorouracil;Vincristine;Etoposide;Irinotecan;Gemcitabine;Oxaliplatin;Sorafenib
13 Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting NCT01015833 Phase 3 Doxorubicin Hydrochloride;Sorafenib Tosylate
14 Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial Terminated NCT01405573 Phase 3 sorafenib
15 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
16 Proof-of-Concept Phase II Study to Evaluate the Anti-Tumor Activity of Sorafenib Along With Pathological and Molecular Changes in Tumor Samples From Patients With Resectable Hepatocellular Carcinoma Unknown status NCT01182272 Phase 2 sorafenib tosylate
17 Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients Unknown status NCT00132041 Phase 2
18 Phase II Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma Unknown status NCT02409524 Phase 2
19 Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02418988 Phase 2 TACE plus rAd-p53 artery injection;TACE
20 A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma Unknown status NCT00471484 Phase 2 doxorubicin hydrochloride;fluorouracil;oxaliplatin
21 Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer) Unknown status NCT00553683 Phase 1, Phase 2 cyclophosphamide;poly ICLC
22 Hepatocellular Carcinoma Family of Tumours In Children / Adolescents and Young Adults Unknown status NCT00276705 Phase 2 cisplatin;cyclophosphamide;doxorubicin hydrochloride;thalidomide
23 A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed NCT02024087 Phase 1, Phase 2 Dalantercept plus sorafenib
24 Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma Completed NCT00005629 Phase 1, Phase 2
25 A Phase II Study of Octreotide Acetate for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma Completed NCT00257426 Phase 2 octreotide acetate
26 A Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma Completed NCT00238394 Phase 2 cediranib maleate
27 A Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation Completed NCT00321594 Phase 1, Phase 2 belinostat
28 Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control Completed NCT00040898 Phase 2
29 Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Completed NCT00006010 Phase 2 docetaxel;gemcitabine hydrochloride
30 Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression Completed NCT00006006 Phase 2 thalidomide
31 A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers Completed NCT00101036 Phase 2 lapatinib ditosylate
32 A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma Completed NCT00087282 Phase 2 alvocidib;irinotecan hydrochloride
33 Phase II Trial of PS-341 in Patients With Hepatocellular Carcinoma Completed NCT00077441 Phase 2 bortezomib
34 A Phase II Study of ZD1839 (Iressa, Gefitinib, NSC 715055) in Advanced Unresectable Hepatocellular Carcinoma Completed NCT00071994 Phase 2 gefitinib
35 A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer Completed NCT00128596 Phase 2 arsenic trioxide
36 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hepatocellular Carcinoma Completed NCT00004108 Phase 2 exatecan mesylate
37 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
38 A Phase II Study Of Epirubicin And Thalidomide In Unresectable Or Metastatic Hepatocellular Carcinoma Completed NCT00058487 Phase 2 epirubicin hydrochloride;thalidomide
39 A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma Completed NCT00054262 Phase 2 T900607
40 A Phase II Study of Oxaliplatin in Hepatocellular Cancer Completed NCT00052364 Phase 2 oxaliplatin
41 Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma Completed NCT00483405 Phase 2 capecitabine;oxaliplatin
42 A Phase 2 Study of IMC-A12 (NSC742460) in Hepatocellular Carcinoma Completed NCT00639509 Phase 2
43 Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients Completed NCT00875615 Phase 2 Carboplatin;Cisplatin;Sorafenib
44 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
45 A Phase II Study Of SB-715992 (NSC 727990) In Patients With Locally Advanced, Recurrent Or Metastatic Hepatocellular Carcinoma Completed NCT00095992 Phase 2 ispinesib
46 A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas Completed NCT00107536 Phase 2 lapatinib ditosylate
47 Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma Completed NCT00335829 Phase 2 chemotherapy;embolization therapy
48 Bevacizumab (RhuMAB-VEGF) In Hepatocellular Cancer For Patients With Unresectable Tumor (Without Invasion Of The Main Portal Vein Or Metastatic Disease) A Phase II Study Completed NCT00055692 Phase 2
49 An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial) Completed NCT00956930 Phase 2 Doxorubicin
50 Continuous Sunitinib Treatment in Patients With Unresectable Hepatocellular Carcinoma A Multicenter Phase II Trial Completed NCT00514228 Phase 2 sunitinib malate

Search NIH Clinical Center for Adult Hepatocellular Carcinoma

Genetic Tests for Adult Hepatocellular Carcinoma

Anatomical Context for Adult Hepatocellular Carcinoma

MalaCards organs/tissues related to Adult Hepatocellular Carcinoma:

41
Liver, Testes, Endothelial, Colon, Bone, Breast

Publications for Adult Hepatocellular Carcinoma

Articles related to Adult Hepatocellular Carcinoma:

(show all 12)
# Title Authors PMID Year
1
Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer. 38
30288475 2018
2
Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. 38
29602016 2018
3
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. 38
26990031 2016
4
Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. 38
24002724 2014
5
FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo. 38
23544173 2013
6
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. 38
21922643 2012
7
Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors. 38
21788913 2012
8
Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. 38
21989430 2011
9
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. 38
19719772 2009
10
Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. 38
18525461 2008
11
Alpha(1)-antitrypsin deficiency, liver disease and emphysema. 38
12672469 2003
12
Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. 38
10847487 2000

Variations for Adult Hepatocellular Carcinoma

Cosmic variations for Adult Hepatocellular Carcinoma:

9 (show top 50) (show all 3365)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 3
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 3
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 3
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 3
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 3
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 3
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 3
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 3
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 3
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 3
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 3
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 3
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 3
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 3
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 3
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 3
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 3
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 3
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 3
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 3
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 3
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 3
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 3
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 3
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 3
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 3
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 3
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 3
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 3
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 3
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 3
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 3
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 3
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 3
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 3
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 3
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 3
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 3
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 3
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 3
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 3
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 3
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 3
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 3
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 3
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 3
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 3
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 3
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 3
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 3

Expression for Adult Hepatocellular Carcinoma

Search GEO for disease gene expression data for Adult Hepatocellular Carcinoma.

Pathways for Adult Hepatocellular Carcinoma

Pathways related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 TSC2 TSC1 TP53 PIK3CA EGF CTNNB1
2
Show member pathways
13.66 TSC2 TSC1 TP53 EGF CTNNB1 CASP8
3
Show member pathways
13.11 TSC2 TSC1 EGF CTNNB1 CASP8 AXIN1
4
Show member pathways
12.81 TSC2 TP53 PIK3CA CTNNB1 CASP8
5
Show member pathways
12.77 TSC2 TSC1 PIK3CA EGF
6
Show member pathways
12.75 TSC2 TSC1 TP53 PIK3CA CTNNB1 CASP8
7
Show member pathways
12.68 TP53 PIK3CA CASP8 AXIN1
8
Show member pathways
12.61 TP53 PIK3CA EGF CTNNB1 AXIN1
9
Show member pathways
12.6 TSC2 TP53 PIK3CA EGF
10
Show member pathways
12.59 TSC2 TP53 PIK3CA EGF CTNNB1 AXIN1
11
Show member pathways
12.55 TSC2 TSC1 TP53 PIK3CA EGF
12
Show member pathways
12.54 TSC2 PIK3CA CTNNB1 CASP8
13 12.52 TP53 PIK3CA EGF CTNNB1 CASP8 AXIN1
14
Show member pathways
12.39 TSC2 TSC1 TP53 PIK3CA EGF CTNNB1
15
Show member pathways
12.35 TP53 CTNNB1 AXIN1
16
Show member pathways
12.33 TP53 PIK3CA CTNNB1 CASP8
17
Show member pathways
12.32 TSC2 TSC1 TP53 PIK3CA
18 12.31 TP53 CTNNB1 AXIN1
19
Show member pathways
12.3 TSC2 TSC1 PIK3CA
20
Show member pathways
12.29 TSC2 TSC1 PIK3CA EGF
21
Show member pathways
12.28 TSC2 TSC1 TP53 PIK3CA
22
Show member pathways
12.27 TSC2 TP53 CASP8
23
Show member pathways
12.27 TSC2 TSC1 TP53 PIK3CA AXIN1
24 12.25 TP53 PIK3CA CTNNB1
25 12.19 TP53 PIK3CA CASP8
26 12.19 TP53 PIK3CA CTNNB1
27
Show member pathways
12.1 TSC2 TSC1 TP53 PIK3CA
28 12.08 TP53 EGF CTNNB1
29
Show member pathways
12.06 PIK3CA EGF CTNNB1
30 12.04 TSC2 TSC1 TP53 PIK3CA
31
Show member pathways
12.02 TSC2 PIK3CA CASP8
32 12.02 TSC2 TSC1 TP53 PIK3CA
33 12 CTNNB1 CASP8 AXIN1
34 11.99 PIK3CA CTNNB1 AXIN1
35
Show member pathways
11.99 TSC2 TSC1 TP53 PIK3CA
36 11.98 TP53 PIK3CA CTNNB1
37 11.97 TSC2 TSC1 PIK3CA
38
Show member pathways
11.96 TSC2 PIK3CA EGF CTNNB1
39 11.95 TP53 CTNNB1 AXIN1
40
Show member pathways
11.92 TP53 PIK3CA CASP8
41 11.83 TSC2 TP53 PIK3CA CTNNB1
42 11.79 TP53 PIK3CA CTNNB1 AXIN1
43 11.78 TSC2 TSC1 PIK3CA
44 11.74 TSC2 TSC1 TP53 CTNNB1 CASP8
45 11.73 TSC2 TSC1 TP53
46 11.66 TP53 PIK3CA CASP8
47 11.6 TP53 CTNNB1 AXIN1
48 11.38 TSC2 TSC1 TP53
49
Show member pathways
11.36 PIK3CA EGF
50 11.33 EGF CTNNB1

GO Terms for Adult Hepatocellular Carcinoma

Cellular components related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.62 TSC2 TSC1 CTNNB1 AXIN1
2 protein-containing complex GO:0032991 9.56 TSC1 TP53 CTNNB1 CASP8
3 lamellipodium GO:0030027 9.33 TSC1 PIK3CA CTNNB1
4 beta-catenin destruction complex GO:0030877 8.96 CTNNB1 AXIN1
5 TSC1-TSC2 complex GO:0033596 8.62 TSC2 TSC1

Biological processes related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.81 TP53 EGF CTNNB1 AXIN1
2 regulation of apoptotic process GO:0042981 9.77 TP53 CTNNB1 CASP8
3 viral process GO:0016032 9.71 TSC2 TP53 CTNNB1 CASP8
4 protein kinase B signaling GO:0043491 9.58 TSC2 PIK3CA
5 negative regulation of TOR signaling GO:0032007 9.58 TSC2 TSC1
6 negative regulation of insulin receptor signaling pathway GO:0046627 9.57 TSC2 TSC1
7 positive regulation of macroautophagy GO:0016239 9.56 TSC2 TSC1
8 negative regulation of cell proliferation GO:0008285 9.56 TSC2 TSC1 TP53 CTNNB1
9 response to antibiotic GO:0046677 9.55 TP53 CASP8
10 ERBB2 signaling pathway GO:0038128 9.54 PIK3CA EGF
11 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.52 EGF AXIN1
12 vasculature development GO:0001944 9.49 PIK3CA CTNNB1
13 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.48 TP53 CASP8
14 beta-catenin destruction complex disassembly GO:1904886 9.46 CTNNB1 AXIN1
15 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.43 EGF AXIN1
16 negative regulation of oxidative stress-induced neuron death GO:1903204 9.37 TSC1 CTNNB1
17 negative regulation of macroautophagy GO:0016242 9.32 TSC1 PIK3CA
18 anoikis GO:0043276 9.16 TSC2 PIK3CA
19 regulation of protein localization to cell surface GO:2000008 8.96 EGF CTNNB1
20 regulation of calcium ion import GO:0090279 8.62 EGF CTNNB1

Molecular functions related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp90 protein binding GO:0051879 9.16 TSC2 TSC1
2 disordered domain specific binding GO:0097718 8.96 TP53 CTNNB1
3 I-SMAD binding GO:0070411 8.62 CTNNB1 AXIN1

Sources for Adult Hepatocellular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....